Enanta Pharma (ENTA) Misses Q1 EPS by 16c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. CVS

Go back to Enanta Pharma (ENTA) Misses Q1 EPS by 16c, Revenues Miss

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018

February 6, 2019 4:01 PM EST

Webcast and Conference Call today at 4:30 p.m. ET

Royalty revenue for the quarter increased to $69.9 million Research and development programs progressing well with clinical milestones expected in 2019 in our RSV, NASH, and HBV programs Cash and marketable securities totaled $357.3 million at December 31, 2018

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported... More